HDAC6 and pulmonary fibrosis: Given that CYLD as a deubiquitinase and HDAC6 as a deacetylase have a number of substrates, it is tempting to investigate other molecular mechanisms underlying CYLD/HDAC6-mediated pulmonary fibrosis and the therapeutic potential for treating this terrible disease with inhibitors targeting CYLD and HDAC6.